Prelude Therapeutics (PRLD) Competitors $1.30 -0.07 (-4.78%) As of 02:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. NLTX, SOPH, VYGR, ABEO, ALLO, ZURA, TKNO, AVTE, PBYI, and OGIShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Neoleukin Therapeutics (NLTX), SOPHiA GENETICS (SOPH), Voyager Therapeutics (VYGR), Abeona Therapeutics (ABEO), Allogene Therapeutics (ALLO), Zura Bio (ZURA), Alpha Teknova (TKNO), Aerovate Therapeutics (AVTE), Puma Biotechnology (PBYI), and Organigram Global (OGI). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Its Competitors Neoleukin Therapeutics SOPHiA GENETICS Voyager Therapeutics Abeona Therapeutics Allogene Therapeutics Zura Bio Alpha Teknova Aerovate Therapeutics Puma Biotechnology Organigram Global Prelude Therapeutics (NASDAQ:PRLD) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings. Does the media refer more to PRLD or NLTX? In the previous week, Prelude Therapeutics had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Prelude Therapeutics and 0 mentions for Neoleukin Therapeutics. Prelude Therapeutics' average media sentiment score of 0.83 beat Neoleukin Therapeutics' score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Prelude Therapeutics Positive Neoleukin Therapeutics Neutral Do institutionals & insiders believe in PRLD or NLTX? 79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 63.9% of Prelude Therapeutics shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, PRLD or NLTX? Prelude Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Is PRLD or NLTX more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -106.50% -79.07% Neoleukin Therapeutics N/A -37.22%-30.91% Which has stronger earnings and valuation, PRLD or NLTX? Neoleukin Therapeutics has lower revenue, but higher earnings than Prelude Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M10.47-$127.17M-$1.64-0.79Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-10.68 Do analysts rate PRLD or NLTX? Prelude Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 208.88%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Prelude Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPrelude Therapeutics beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks. Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.30M$3.03B$6.15B$10.47BDividend YieldN/A57.77%5.73%4.78%P/E Ratio-0.7923.0085.0727.24Price / Sales10.47621.94573.51178.32Price / CashN/A172.6337.3961.86Price / Book0.545.4412.426.70Net Income-$127.17M$33.06M$3.32B$276.79M7 Day Performance-7.50%-0.98%0.28%-0.86%1 Month Performance11.64%13.14%10.06%6.26%1 Year Performance-33.25%-2.14%72.23%37.64% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics3.4356 of 5 stars$1.30-4.8%$4.00+208.9%-28.8%$73.30M$7M-0.79120NLTXNeoleukin TherapeuticsN/A$30.21-4.3%N/A-33.6%$283.91MN/A-9.7190High Trading VolumeSOPHSOPHiA GENETICS2.2819 of 5 stars$4.04-3.3%$8.00+98.0%+24.0%$282.48M$65.17M-9.18520News CoverageGap UpVYGRVoyager Therapeutics4.0236 of 5 stars$4.89-2.2%$13.25+170.9%-22.8%$277.34M$80M-2.64100ABEOAbeona Therapeutics4.3915 of 5 stars$5.41+0.9%$19.50+260.4%-15.4%$274.85M$3.50M7.7390Analyst ForecastALLOAllogene Therapeutics2.5933 of 5 stars$1.27+3.3%$8.44+564.9%-53.1%$272.91M$20K-1.14310ZURAZura Bio3.0833 of 5 stars$3.86-7.0%$11.60+200.5%-10.8%$269.83MN/A-5.513Analyst ForecastTKNOAlpha Teknova2.0903 of 5 stars$5.01+1.0%$10.00+99.6%-12.9%$265.43M$37.74M-11.93240AVTEAerovate TherapeuticsN/A$9.08-3.4%N/A-87.6%$263.18MN/A-3.0420News CoverageHigh Trading VolumePBYIPuma Biotechnology4.136 of 5 stars$5.29+3.3%$7.00+32.3%+93.0%$257.90M$230.50M5.40200Positive NewsOGIOrganigram Global1.0203 of 5 stars$1.92+0.5%N/A+13.3%$256.59M$117.47M38.41860News Coverage Related Companies and Tools Related Companies Neoleukin Therapeutics Alternatives SOPHiA GENETICS Alternatives Voyager Therapeutics Alternatives Abeona Therapeutics Alternatives Allogene Therapeutics Alternatives Zura Bio Alternatives Alpha Teknova Alternatives Aerovate Therapeutics Alternatives Puma Biotechnology Alternatives Organigram Global Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredThe Final DisplacementA new documentary called The Final Displacement is stirring major controversy — and for good reason. It expose...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
